A practical reference on albumin binding: what it is, how it behaves, what the literature reports, and where the honest uncertainties sit.
This page was last updated on 2026-01-22 and is reviewed periodically as new material appears.
The peptide binds GHRH receptors on somatotroph cells within the anterior pituitary, triggering a signalling cascade that increases growth hormone secretion. Its improved resistance to dipeptidyl peptidase IV degradation distinguishes it from the parent hormone. In the DAC-bearing version, a maleimide group reacts with a cysteine residue on serum albumin, forming a covalent bond that keeps the peptide in circulation far longer. That albumin attachment is the central design feature separating the two research variants.
Pharmacokinetic behaviour differs sharply between the two forms. The DAC-bearing peptide shows an extended circulation time measured in days, whereas the version without the complex is cleared within roughly half an hour. This gap shapes how researchers design dosing schedules in animal models. Whether the prolonged presence of the DAC form produces effects meaningfully different from the short-acting variant remains an open question, since comparative human data are scarce.
CJC-1295 is a synthetic peptide designed to mimic growth hormone-releasing hormone (GHRH), the endogenous signal that prompts the pituitary gland to release growth hormone. The compound is a modified fragment of the natural hormone, spanning the first twenty-nine amino acids of GHRH with several substitutions that slow enzymatic breakdown. Two variants circulate in research settings: one carrying a drug affinity complex (DAC) and one without it. The DAC-free form is frequently labelled Mod GRF(1-29) in catalogs and discussion forums.
Batch-to-batch consistency depends on solid-phase peptide synthesis and subsequent purification. Coupling efficiency, resin choice, and cleavage conditions all affect the final profile. Counter-ion content and moisture can shift the apparent mass of a batch. Documentation typically includes a certificate of analysis with chromatograms and spectra. Independent verification by a second laboratory is sometimes requested. Whether a given certificate reflects the actual vial contents depends on chain of custody. Analytical methods themselves carry uncertainty that should be stated alongside results.
Lyophilized material is typically stored at minus twenty degrees Celsius or lower. Keeping the vial dry and protected from light preserves peptide integrity. Repeated freeze-thaw cycles can cause aggregation or loss of activity. Once dissolved, solutions are generally kept at two to eight degrees Celsius. Stability data for reconstituted solutions vary, and long-term behavior is not fully established. Working aliquots reduce the number of times a stock container is opened.
Reverse-phase high-performance liquid chromatography is the standard tool for purity assessment. The technique separates the target peptide from truncated or modified byproducts. Mass spectrometry confirms molecular weight and supports sequence verification. Electrospray ionization and matrix-assisted laser desorption are both used. Amino acid analysis provides an independent check on composition. Purity values are commonly reported as area percentage from the chromatogram. Residual trifluoroacetate and water content are also measured in many quality programs.
| Property | Value | Notes |
|---|---|---|
| Molecular weight (with DAC) | ~3647 Da | Calculated from the full amino acid sequence |
| Molecular weight (without DAC) | ~3368 Da | Mod GRF(1-29) variant |
| Appearance | White lyophilized powder | Typical form supplied for research |
| Solubility | Soluble in water | Dissolves in aqueous buffers |
| Receptor target | GHRH receptor | Expressed on pituitary somatotroph cells |
The core sequence keeps the receptor-binding region of GHRH while replacing four positions that are vulnerable to dipeptidyl peptidase-4 and other proteases. Substitutions at positions 2, 8, 15, and 27 raise metabolic stability relative to the natural hormone. The N-terminal residues remain essential for activity, so changes there generally lower potency. Molecular weight sits near 3368 daltons for the tetrasubstituted analog without the linker, while the albumin-binding form is heavier because of the added maleimide group.
CJC-1295 is a synthetic peptide modeled on growth hormone-releasing hormone, the hypothalamic signal that prompts the pituitary to release growth hormone. Its sequence corresponds to the first twenty-nine residues of human GHRH, with four substitutions that slow enzymatic breakdown. Early descriptions placed the compound in research on growth hormone deficiency and related conditions, and later literature groups it with the long-acting GHRH analogs. The name appears in both laboratory and popular fitness writing, where it sometimes labels chemically different peptides.
Analytical confirmation usually relies on reversed-phase high-performance liquid chromatography for purity and on liquid chromatography coupled to mass spectrometry for identity. Mass data reveal the expected molecular mass and can flag truncated or oxidized species. Amino acid analysis and peptide mapping provide sequence-level verification. Immunoassays are used in some biological matrices, but antibodies raised against one releasing-hormone analog may cross-react with another. Reported purity figures depend heavily on the method used, so comparisons between suppliers require matching the analytical approach.
The two variants differ dramatically in how long they persist in circulation. The form lacking the albumin-binding group has a plasma half-life measured in tens of minutes, comparable to the natural hormone fragment. The version carrying the drug affinity complex binds albumin and shows a half-life of roughly six to eight days in human studies. That figure comes from small trials that tracked hormone levels over extended periods. The physiological consequences of sustained versus pulsatile stimulation are still debated and the literature does not settle the point.
Lyophilized peptide powder is comparatively stable when kept dry, cold, and protected from light. Once dissolved, the molecule is vulnerable to deamidation, oxidation, and aggregation, with the rate depending on pH, buffer composition, and temperature. Alkaline conditions and repeated freeze-thaw cycles accelerate loss of the intact peptide. The methionine present in the native sequence is a known oxidation site, which is one reason it was replaced in the modified fragment. Suppliers typically recommend cold storage of solutions and use within a short window.
Two forms circulate in research settings and are frequently confused. One carries the drug affinity complex and is often written as CJC-1295 with DAC; the other lacks that group and is usually called modified GRF(1-29). The two share the same core sequence but differ sharply in how long they persist in blood. Products labelled only as CJC-1295 normally refer to the version carrying the complex. Documentation that omits the distinction leaves the intended molecule ambiguous.
CJC-1295 is a synthetic peptide built as a long-acting analogue of growth hormone-releasing hormone. Its backbone matches the first twenty-nine residues of the natural human hormone, with four amino acid substitutions added to slow enzymatic breakdown. A reactive maleimide group, commonly termed the drug affinity complex, allows the peptide to attach to circulating albumin after administration. That albumin attachment keeps the molecule in the bloodstream for an extended period instead of being cleared within minutes.
The compound emerged from work at a Canadian biotechnology firm in the early 2000s. Early human studies examined its effect on growth hormone and insulin-like growth factor 1 in healthy volunteers and in people with HIV-associated fat redistribution. Reports described sustained increases in both markers after a single injection. Development did not advance to regulatory approval, and the clinical programme was later discontinued. The molecule is now encountered mainly as a research chemical rather than a marketed medicine.
The isotopes neptunium-235, -236, and -237 are predicted to be fissile; although only neptunium-237's fissionability has been experimentally shown. Its critical mass is about 60 kg, only about 10 kg more than that of the commonly used uranium-235. Calculated values of the critical masses of neptunium-235, -236, and -237 respectively are 66.2 kg, 6.79 kg, and 63.6 kg: the neptunium-236 value is even lower than that of plutonium-239 and 236Np also has a low neutron cross section. However, a neptunium atomic bomb has never been built because uranium and plutonium have lower critical masses than 235Np and 237Np, and 236Np is difficult to purify as it is not found in quantity in spent nuclear fuel and is nearly impossible to separate in any significant quantities from 237Np.
The 2014 Farm Bill legalized the sale of "non-viable hemp material" grown within states participating in the Hemp Pilot Program which defined hemp as cannabis containing less than 0.3% of THC. The 2018 Farm Bill removed the hemp plant and all "derivatives, extracts, cannabinoids, isomers, acids, salts, and salts of isomers, whether growing or not, with a delta-9 tetrahydrocannabinol concentration of not more than 0.3 percent on a dry weight basis," including CBD, from the Controlled Substances Act, making them legal to manufacture in the United States. The FDA retains regulatory authority over hemp-derived CBD, while the DEA is not involved in the regulation of legally-compliant hemp and hemp products. The 2018 Farm Bill requires that research and development of CBD for a therapeutic purpose would have to be conducted under notification and reporting to the FDA. On April 23, 2026, the Department of Justice issued an order to immediately reclassify medical cannabis as a Schedule III controlled substance when dispensed by a state-licensed cannabis dispensary. The DEA is in the process of conducting expedited public hearings to address the broader rescheduling of all cannabis from Schedule I to Schedule III, with the hearings scheduled to begin June 29, 2026.
== Aftermath == After returning to France in August 1804, Alexander von Humboldt and Aimé Bonpland arrived in Bordeaux after a swift Atlantic crossing. Their return after six years abroad was marked by the need to adjust to changed circumstances and reintegrate into European life. During quarantine, Humboldt wrote to the Institut National in Paris, informing them of his safe arrival. This news caused surprise, as rumors of his death had circulated in Europe. Humboldt reached Paris in late August, looking healthy and energetic. He was warmly welcomed by friends and family, with accounts noting he appeared unchanged by his long absence. Parisian society celebrated Humboldt as a hero. He was honored at scientific meetings and social gatherings, gaining widespread public attention for his South American explorations. His collections and drawings, exhibited at the Jardin des Plantes, attracted large crowds. Within six weeks, the Institut National held a special meeting where Humboldt presented his scientific results, receiving enthusiastic applause. In mid-October, Humboldt presented the first reports of his journey at a meeting of the Institut National des Sciences et Arts, a French government organisation created in 1795 to promote science, the beaux arts, and literature. The meeting was crowded and highly anticipated. In October of that year, the inaugural exhibition of Humboldt's botanical collection was inaugurated at the Jardin des Plantes, where it met with considerable acclaim.
^ 1 On early U.S. and Canadian pressings, "Down in a Hole" appeared as track 12 placed between "Angry Chair" and "Would?". Current U.S. and Canadian editions of the CD and the Vinyl have "Down in a Hole" as the fourth track, located between "Rain When I Die" and "Sickman", which was the track listing that the band originally intended before the record company changed the order. ^ 2 Track 9 or 10, "Iron Gland", appears without a title on the album. The title appeared on the compilations Nothing Safe and Music Bank. The iTunes Store lists it incorrectly as "Iron Man". Before the name "Iron Gland" was revealed, it was labeled in some online databases as "Intro (Dream Sequence)". On editions in which "Down in a Hole" is track 4, "Iron Gland" is track 10. The track is unlisted on some versions of the album, and some editions remove the track completely or merge it with "Hate to Feel". On the back cover of the edition in which "Iron Gland" is track 9, "Hate to Feel", "Angry Chair", "Down in a Hole" and "Would?" are listed from 9–12. However, when the CD is played, the songs are on tracks 10–13.
Myrophine (Myristylbenzylmorphine) is an opiate analogue that was developed in 1952. It is a derivative of morphine. Myrophine is substituted with a 3-benzyl group and a 6-myristyl chain. It is metabolised to form benzylmorphine and then further to morphine, and so is a long-acting prodrug for morphine, but with a slow onset of effects. It is weaker than morphine as an analgesic but longer-lasting in effects, and was thought to have more local anesthetic effect than morphine, though with a somewhat greater tendency to cause reactions like itching and rash. In addiction studies conducted in human subjects in the 1950s, myrophine did not substitute for morphine in withdrawal, did not produce notable morphine-like effects, and did not produce addiction or dependence regardless of dose or how it was administered. Consequently, it was thought to be useful in treating pain in addicts who were being detoxified from other opioid drugs. It is a Schedule I drug in the US, considered to have high potential for abuse and no medical applications, and is controlled under international drug conventions. Myrophine is almost invariably used as the hydrochloride (free base conversion ratio 0.94) and has a DEA Administrative Controlled Substance Control Number of 9308. Myrophine is a Class A controlled substance in the UK, and is on the UN's Yellow list.
Sources: en.wikipedia.org
Adrenomedullin (ADM) is a peptide hormone that plays an important role in various physiological processes throughout the human body. Initially discovered in 1993 from a pheochromocytoma, a tumor of the adrenal medulla, this 52-amino acid peptide is now recognized for its diverse effects, including vasodilation, regulation of blood pressure, and maintenance of the vascular system. ADM is widely expressed in tissues and also found in the circulation, exerting its influence on the cardiovascular, lymphatic, and endocrine systems, as well as demonstrating anti-inflammatory and tissue-protective properties. In humans, ADM is encoded by the ADM gene. A similar peptide named adreomedullin2 was reported in rats in 2004, which exhibits a similar function.
Eventually, both Manlu and Zhu feel remorse of their misdeeds toward Manzhen, and Manlu begs her sister to come back to raise her nephew/stepson with her husband after they locate her, asking for forgiveness before she dies. Despite still hating them for the rape, Manzhen stays with Zhu for the sake of their son. By chance, Manzhen and Shijun reunite in Shanghai, and both talk of each other's lives years after their separation. Knowing that they still love each other, but due to the restrictions of their respective obligations, both Manzhen and Shijun realize that they cannot be together.
=== Legal status === Empagliflozin/metformin was approved for use in the European Union in May 2015. Empagliflozin/metformin was approved for use in the United States in August 2015. The extended release version was approved for use in the United States in December 2016. Empagliflozin/metformin was approved for use in Australia in May 2020.
=== Rest of 2008 === Secretary General of the Council of Europe Terry Davis said on 1 October 2008 that although he was critical of Georgian actions, Georgia was not the aggressor because it did not carry out a military operation against a sovereign state. In late October 2008, French Foreign Minister Bernard Kouchner in his interview with Kommersant said that during the war "there was a real danger of regime change in Georgia". He also said that "...Russia without question was prepared. Russian troops, by some miracle, turned up on the border at the right time." He stated that the next hot spots could become Crimea, Ukraine and others. On 28 October 2008, Brigadier general Mamuka Kurashvili, a Georgian military official, told the parliamentary commission that his "impulsive" description of the military operation as an action "to restore constitutional order" was not sanctioned by superiors and he was "confused" as he had just returned from a battle. He also stated that Russian commander Marat Kulakhmetov's statements that he could not restrain the South Ossetian militants was "a lie." On 29 October 2008, Minister of Internal Affairs of Georgia Vano Merabishvili told Kommersant that "Putin wants to go down in Russian history as collector of lands." He said that the Georgian villages in South Ossetia had to be defended from ethnic cleansing and that from 1 August 2008, Georgians living in South Ossetia "were Kokoity's hostages".
Food and Drug Administration Food hygiene: example Clinical laboratory medicine: ISO 15198:2004 Clinical laboratory medicine—In vitro diagnostic medical devices—Validation of user quality control procedures by the manufacturer Engineering Engineering in general Engineering validation test Civil engineering Buildings – Roads – Bridges – Health care: example Greenhouse gas: ISO 14064 ANSI/ISO: Greenhouse gases – Requirements for greenhouse gas validation and verification bodies for use in accreditation or other forms of recognition Traffic and transport Road safety audit Periodic motor vehicle inspection Aircraft noise: example Aircraft: Model: (Ni-Cd) cells: example ICT Industry: example Accounting Agriculture – applications vary from verifying agricultural methodology and production processes to validating agricultural modeling Real estate appraisal – audit reporting and authentication Arms control
Sources: en.wikipedia.org
The synthetic peptide keeps the receptor-binding region of GHRH but carries substitutions that resist enzymatic cleavage. In the DAC version, an added group also anchors the molecule to albumin, extending its presence in the bloodstream.
The maleimide group forms a covalent link with albumin, an abundant blood protein. This attachment slows clearance, so a single administration persists much longer than the unmodified peptide. The feature is the main reason the two variants are handled differently in study design.
It is not an approved therapeutic product in major regulatory jurisdictions. It appears in research chemical catalogs and scientific literature rather than pharmacy shelves. Clinical development was limited and did not reach approval.
The powder is normally held at minus twenty degrees Celsius or below. Light and moisture exposure should be minimized. Repeated warming and cooling cycles are avoided.